Page 2061 — thrombosed dialysis access: recognition, salvage window, thrombectomy, culprit stenosis, and function confirmation
Every functioning arteriovenous (AV) fistula or graft has a signature: a continuous, buzzing "thrill" felt under the fingertips over the outflow vein, and a low-pitched "bruit" heard through a stethoscope, both generated by high-velocity, turbulent blood crossing the arteriovenous anastomosis. When the access clots, that signature vanishes almost instantly — the segment becomes firm, tender, and non-compressible, with no vibration and no sound. Recognizing this change, whether by the patient, the dialysis nurse, or the physician, is the first and most time-critical step in access salvage, because everything that determines procedural success from this point forward is a function of how quickly the clot is addressed.
Palpation (thrill): • Patent access: continuous, low-amplitude buzzing vibration felt over the entire outflow tract, strongest near the anastomosis, softening distally. • Thrombosed access: thrill absent; instead a firm, rope-like, pulsatile (arterial pulse only, no augmented flow) segment is palpated.
Auscultation (bruit): • Patent access: continuous "machinery" murmur, systolic and diastolic components, heard with the stethoscope diaphragm along the length of the vein or graft. • Thrombosed access: bruit absent or reduced to a faint, high-pitched, to-and-fro sound localized only proximal to the clot.
Other clues at the bedside: • New difficulty with cannulation, or the dialysis needle draws no blood. • Arterialized segment feels unusually hard or "woody" compared to the patient's baseline exam. • Occasionally: pain, swelling, or a change in limb color if thrombosis extends or compromises collateral flow.
Why immediate recognition matters: • Access thrombosis is a mechanical problem (clot occluding the lumen) layered on a physiologic one (loss of dialysis access) — every hour without patent access is an hour closer to needing a temporary catheter. • Delayed recognition allows the thrombus to organize and adhere, directly lowering the technical and clinical success rate of any subsequent declotting attempt.
Not all clots are equal. A thrombus that formed minutes to hours ago is soft, gelatinous, and loosely attached — it can be fragmented and aspirated with relatively little force. Given time, however, thrombus undergoes organization: platelets and fibrin cross-link into a denser meshwork, and fibroblasts begin laying down early fibrous tissue that adheres the clot to the endothelium or graft wall. This transformation is the biological clock behind every declotting procedure — it is why access teams treat "time since occlusion" as a primary triage variable, not a secondary detail.
Fresh (hyperacute) thrombus: • Composed predominantly of red cells trapped in a loose fibrin network. • Mechanically fragile — readily disrupted by catheter maceration, balloon dragging, or mechanical thrombectomy devices. • Highly responsive to thrombolytic agents because the drug can penetrate the loosely packed clot matrix.
Organizing thrombus (days): • Fibrin cross-linking increases; platelets degranulate and the clot retracts, becoming denser and more rubbery. • Early fibroblast ingrowth begins to tack the thrombus to the vessel or graft wall at focal points. • Mechanical devices must apply more force; pharmacologic agents penetrate less effectively — success rates measurably decline.
Chronic organized thrombus (weeks): • Thrombus may be largely replaced by fibrous tissue firmly incorporated into the wall. • Endovascular declotting is frequently unsuccessful; surgical thrombectomy or access revision/replacement becomes the more realistic option.
Practical triage implication: • "Hours since thrombosis noted" is used as a working proxy for true clot age, since exact onset is often uncertain — patients may not notice the access failed until the next dialysis session. • The same triage logic that governs stroke and myocardial infarction salvage windows applies here: shorter time-to-treatment directly and substantially improves the odds of restoring a usable access.
Once vascular access is obtained into the thrombosed segment, the declotting procedure itself combines two complementary strategies: mechanical disruption of the clot (using balloon catheters, rotational or hydrodynamic thrombectomy devices, or simple maceration) and pharmacologic dissolution (local infusion of a thrombolytic agent directly into the clot). Used together — the pharmacomechanical approach — these techniques clear the access circuit faster and more completely than either strategy alone, restoring a channel from arterial inflow, through the fistula or graft body, to venous outflow.
Access into the clotted segment: • Two sheaths are typically placed — one directed toward the arterial anastomosis, one toward venous outflow — so the entire circuit can be treated in both directions.
Pharmacologic component: • A thrombolytic agent is infused directly into the thrombus (lace-and-wait or pulse-spray technique), softening the clot matrix before mechanical work begins.
Mechanical component: • Balloon catheters are dragged through the clot to macerate and displace it toward the venous outflow, where fragments are pushed into the central circulation or actively aspirated. • Dedicated mechanical thrombectomy devices (rotational, hydrodynamic, or aspiration-based) accelerate clearance of bulkier or more adherent clot.
Clot fragment management: • Fragments are aspirated back through the sheath whenever possible to minimize embolization risk. • Small distal pulmonary emboli from graft thrombectomy are usually clinically silent given the low volume typically involved, but are a recognized consideration.
Endpoint of this stage: • Restoration of a continuous, angiographically open lumen through the treated segment — the necessary but not sufficient condition for a successful declot, since an underlying stenosis must still be identified and treated (Stage 4).
Thrombosis of a dialysis access almost never occurs in a structurally normal circuit. In the large majority of cases, an untreated stenosis — most often at the venous anastomosis, in the cannulation zone, or more centrally in the outflow vein — has been silently restricting flow for weeks, creating the sluggish, turbulent conditions in which clot forms. If the declotting procedure clears the thrombus but leaves this culprit lesion untreated, the access is left exactly as vulnerable as it was the day before it clotted, and early rethrombosis is the predictable result. A completion angiogram of the entire circuit, followed by angioplasty of any significant lesion, is therefore considered an integral part of the procedure — not an optional add-on.
Completion angiogram: • Performed after thrombus clearance, with contrast injected to visualize the entire circuit — arterial inflow, anastomosis, fistula/graft body, cannulation zone, and central venous outflow. • Any residual narrowing (>50% diameter reduction is the conventional threshold) is flagged as hemodynamically significant and a likely contributor to the thrombotic event.
Angioplasty of the culprit lesion: • A balloon catheter sized to the adjacent normal vessel diameter is positioned across the stenosis and inflated to high pressure, fracturing the fibrointimal hyperplasia that narrowed the lumen. • Elastic recoil, a residual waist on the balloon, or early recurrent stenosis may prompt placement of a stent or stent graft, particularly at the venous anastomosis of a graft.
Why this step defines long-term success: • Clearing thrombus restores flow today; treating the culprit stenosis is what prevents the access from clotting again next week. • Registries consistently show that declotting procedures paired with angioplasty of an identified lesion achieve substantially better subsequent patency than thrombectomy alone.
Skipping angioplasty of an identified culprit stenosis is the single most avoidable cause of early rethrombosis after an otherwise technically successful declot — the clot is only the symptom; the stenosis is the disease.
A declotting procedure is not complete when the final angiographic image looks clean — it is complete when the access is confirmed to work. After thrombus clearance and treatment of any culprit stenosis, the same bedside exam used to detect thrombosis in Stage 1 is repeated: a strong, continuous thrill should be palpable along the outflow tract, and a soft, low-pitched bruit should be audible. Adequate flow should be sufficient to support the next dialysis session without difficulty. This final confirmation step closes the loop and distinguishes a truly functional access from one that is merely angiographically patent on the table.
Immediate bedside confirmation: • Palpation: continuous thrill restored along the length of the access, strongest near the anastomosis. • Auscultation: continuous machinery bruit restored, without the high-pitched, localized sound characteristic of residual stenosis or turbulence. • Sheaths are removed and hemostasis achieved once flow and hemodynamics are satisfactory.
Objective confirmation (when used): • Duplex ultrasound flow-volume measurement can quantify restored flow and confirm resolution of any residual narrowing. • Some programs re-image or re-cannulate under direct visualization at the next dialysis session to confirm functional adequacy in practice, not just in the procedure suite.
Why this final step is not a formality: • A circuit can look angiographically open yet still deliver inadequate flow if a subtle residual lesion, spasm, or incomplete thrombus clearance persists. • Documenting a clear exam and adequate flow at the end of the case is the outcome that actually matters to the patient: a working access for the next dialysis treatment, achieved fastest and most durably when recognition was prompt (Stage 1–2) and the culprit stenosis was treated (Stage 4).